Jupiter Life Line Hospitals Ltd (JLHL)
🎯 Key Takeaways
- Jupiter Life Line Hospitals Ltd is transitioning from a mature hospital operations model toward diversified healthcare services, marked by strategic entry into pharmaceutical manufacturing. The company has executed a ₹3.
- Revenue grew 6% QoQ to ₹411 in Q1FY27.
- ⚠️ 1) The Dombivli Hospital segment currently generates an EBITDA loss of ₹2-3 crores monthly and requires 1.5-2 years to breakeven, posing near-term cas
📖 The Story
Jupiter Life Line Hospitals Ltd is transitioning from a mature hospital operations model toward diversified healthcare services, marked by strategic entry into pharmaceutical manufacturing. The company has executed a ₹3.78 crore acquisition of Sulcus Private Limited and appointed a new CFO to support growth ambitions, while maintaining stable profitability in core hospital operations. This phase reflects deliberate expansion beyond traditional healthcare delivery into higher-margin ancillary segments.
📰 What's Happening
In Q1 FY2026, the company finalized the acquisition of Sulcus Private Limited for ₹3.78 crores to establish pharmaceutical manufacturing capabilities and appointed Harshad Purani as CFO effective July 31, 2026. The board approved unaudited financial results showing consolidated revenue of ₹1,913.80 crores and profit before tax of ₹371.89 crores. Management highlighted plans for a ₹35-40 crore investment over 1-2 years to build a dedicated pharmaceutical manufacturing facility, signaling a strategic pivot toward product-based growth beyond hospital services.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 394 | 365 | 388 | 411 |
| Operating Profit | 71 | 62 | 66 | 53 |
| OPM % | 18.0% | 16.9% | 17.0% | 12.8% |
| Net Profit | 57 | 43 | 50 | 38 |
| EPS | ₹8.75 | ₹6.49 | ₹7.66 | ₹5.72 |
Revenue has grown steadily from ₹365 crores (Dec 2025) to ₹411 crores (Jun 2026), with operating margins holding firm at 12.8-18% despite seasonal fluctuations. Profitability remains consistent, with net profit declining slightly from ₹57 crores (Sep 2025) to ₹38 crores (Jun 2026), primarily due to operational drag from Dombivli Hospital. However, core metrics like OPM and EPS remain stable, indicating disciplined cost management. The financial trend supports management's stated focus on scaling pharmaceutical operations without compromising core hospital profitability.
🔮 Management Outlook & What's Next
Management has not provided explicit forward guidance on revenue or earnings growth in the latest filings, but has indicated plans to invest ₹35-40 crores over 1-2 years in pharmaceutical manufacturing infrastructure. This expansion is framed as a strategic diversification initiative to reduce reliance on hospital-only revenue streams. No specific timelines or ROI expectations were disclosed in the Q1 FY2026 results or board meeting materials.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 66 | 66 | 66 | 66 |
| Reserves | 1,193 | 1,291 | 1,385 | 1,479 |
| Borrowings | 0 | 393 | 403 | 509 |
| Total Liabilities | 1,394 | 1,936 | 2,023 | 2,383 |
| Fixed Assets | 748 | 973 | 993 | 1,384 |
| Investments | 83 | 507 | 526 | 486 |
| Total Assets | 1,394 | 1,936 | 2,023 | 2,383 |
The balance sheet shows a stable capital structure with equity of ₹66 crores and reserves growing from ₹1,291 crores (Mar 2025) to ₹1,479 crores (Mar 2026), reflecting retained earnings. Borrowings have increased modestly from ₹393 crores to ₹509 crores, suggesting active but measured leverage to fund expansion. Total assets rose to ₹2,383 crores, indicating successful asset base growth aligned with strategic investments. The company is financing growth through a combination of internal accruals and debt, maintaining a conservative D/E ratio of 0.33.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2026 |
|---|---|
| Operating | +268 |
| Investing | -442 |
| Financing | +136 |
| Net Cash Flow | -38 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 40.9% | 40.9% | 40.9% | 40.9% |
| FII | 9.1% | 8.5% | 8.5% | 9.4% |
| DII | 17.0% | 17.4% | 17.0% | 16.5% |
| Public | 24.4% | 24.4% | 24.5% | 25.1% |
| # Shareholders | 34,361 | 33,620 | 32,985 | 33,194 |
Institutional investor interest has strengthened, with FII holding rising from 8.48% (Q4FY26) to 9.37% (Q1FY27), while DII increased from 16.96% to 17.01%. Promoter holding remains stable at 40.91%. The growing number of public shareholders (33,194 in Q1FY27) suggests rising retail interest. No insider selling or significant dilution is evident, and the shareholding pattern reflects broadening investor confidence ahead of the pharmaceutical expansion.
⚖️ Peer Comparison — Healthcare
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| APOLLOHOSP | 1.25 L Cr | 60.0 | 22.1% | 22.9% | 0.60 |
| MAXHEALTH | 1.00 L Cr | 68.9 | 14.4% | 13.6% | 0.27 |
| MANIPALHOS | 93,977 | — | — | — | 1.25 |
| FORTIS | 65,568 | 62.6 | 13.3% | 10.8% | 0.29 |
| ASTERDM | 64,587 | 119.9 | 12.9% | 8.6% | 0.17 |
| NH | 37,845 | 46.1 | 13.7% | 18.0% | 1.07 |
| MEDANTA | 37,775 | 67.9 | 21.9% | 16.3% | 0.10 |
| KIMS | 32,233 | 150.5 | 9.7% | 8.7% | 1.44 |
| LALPATHLAB | 31,751 | 45.7 | 29.6% | 21.8% | 0.00 |
| POLYMED | 17,302 | 54.9 | 15.1% | 11.3% | 0.06 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) The Dombivli Hospital segment currently generates an EBITDA loss of ₹2-3 crores monthly and requires 1.5-2 years to breakeven, posing near-term cash flow pressure. 2) The pharmaceutical manufacturing venture is capital-intensive with a ₹35-40 crore investment plan and unproven scalability. 3) The merger with Medulla Healthcare remains pending regulatory approval and is not material to current results, creating uncertainty around long-term strategic integration. 4) Limited analyst coverage and low public float may amplify volatility around strategic announcements.
📋 Recent Filings
-
🔴 Announcement 15 September 2026Jupiter Life Line Hospitals announced its schedule for upcoming investor meetings, including an in-person conference with PL Capital on September 28, ...
-
Announcement 7 August 2026Jupiter Life Line Hospitals reported Q1 FY27 revenue of INR411 crores, EBITDA of INR79.3 crores (19.3% margin), and PAT of INR37.5 crores. Dombivli Ho...
-
Announcement 3 August 2026Jupiter Life Line Hospitals Limited announced that the audio recording of its Q1 FY27 earnings conference call held on August 3, 2026 at 10:00 AM IST ...
-
🔴 Financial Results 31 July 2026Jupiter Life Line Hospitals Limited announced its Q1 FY2026 unaudited financial results on July 31, 2026, reporting revenue of **₹1,913.80 crores**, p...
-
🔴 Financial Results 31 July 2026Jupiter Life Line Hospitals Limited announced its unaudited Q1 FY2026 results on July 31, 2026, reporting consolidated revenue of **[amount context mi...
-
🟡 Board Meeting 31 July 2026The Board of Jupiter Life Line Hospitals Limited approved unaudited financial results for Q1 FY2026 ending June 30, 2026, reporting revenue of **₹1,91...
-
Announcement 27 July 2026Jupiter Life Line Hospitals announced an earnings conference call for Q1 FY27 on August 3, 2026 at 10:00 AM IST to discuss operational and financial p...
-
share transfer 6 July 2026Jupiter Life Line Hospitals Limited received a SEBI-mandated certificate from its share transfer agent confirming all shares remained fully dematerial...
-
🟡 concall transcript 30 June 2026Jupiter Life Line Hospitals reported Q1 FY27 revenue of INR411 crores, EBITDA of INR79.3 crores (19.3% margin), and PAT of INR37.5 crores. Dombivli Ho...
-
🔴 annual report 29 June 2026Jupiter Life Line Hospitals Limited disclosed that its Annual Report for FY 2025-26 and the 24th AGM notice are available on its website, urging share...
🧠 Analyst's Read
Jupiter Life Line Hospitals is executing a deliberate transition from hospital-centric operations to a diversified healthcare platform, with pharmaceutical manufacturing as the next growth vector. Investors should monitor execution of the ₹35-40 crore capex plan and breakeven timeline for Dombivli Hospital, as near-term profitability may face headwinds from phased expansion.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-17.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when JLHL files new disclosures
Track JLHL filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track JLHL — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd